REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - MaxCyte Appoints Cynthia Collins to Board

MaxCyteAnnouncement

15/10/2024 13:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241015:nRSO2348Ia&default-theme=true

RNS Number : 2348I  MaxCyte, Inc.  15 October 2024

MaxCyte Appoints Cynthia Collins to its Board of Directors

 

 

Rockville, MD, Oct. 15, 2024 - MaxCyte, Inc.
(https://protect.checkpoint.com/v2/___https:/maxcyte.com/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzo5NGRhMmRhOGUwZjZhMzIxM2QzMTEzMDQ2YjA0ZjQzYjo2Ojk2MGQ6M2Q0Y2M0Y2IyMzI3OGExYjcwZmZiN2YxMzNhMDYzYmY2YzNiMDBiMzZlMDQwNGVmM2JmOTc2M2U1NDMxYTc2YzpwOkY6Rg)
, (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company
providing enabling platform technologies to advance the discovery, development
and commercialization of next-generation cell-based therapeutics and
innovative bioprocessing applications, today announced the appointment of
Cynthia Collins to the Company's Board of Directors as a non-executive
director, effective October 14, 2024. Collins will serve on the board's
compensation committee. Following her appointment, MaxCyte's total Board of
Directors will increase to 10 members.

 

"I am pleased to welcome Cynthia to MaxCyte's Board of Directors," said Maher
Masoud, President and CEO of MaxCyte. "Cynthia has extensive and impressive
leadership experience in the fields of cell therapy and genetic medicine that
will be invaluable to MaxCyte in the coming years. I look forward to working
alongside her to enable a growing set of next-generation cell therapies as the
premier cell engineering platform in our industry."

 

Ms. Collins brings over 40 years of experience in the biotechnology industry
and cell and gene medicines to MaxCyte, including her most recent role as
Chief Executive Officer of Editas Medicine, where she was involved in dosing
the first patient ever with an in-vivo gene modified therapy. Previously, Ms.
Collins served as Chief Executive Officer of Human Longevity Inc., Chief
Executive Officer/General Manager of General Electric Healthcare's Cell
Therapy and Lab Businesses, and Chief Executive Officer of GenVec, Inc., a
vaccine and gene therapy company.

 

Currently, Ms. Collins serves as a member of the Board of Directors of several
healthcare companies, including Alanis Therapeutics, Nutcracker Therapeutics,
Poseida Therapeutics (Nasdaq: PSTX), Certara (Nasdaq: CERT), DermTech (OTC:
DMTKQ), Draper Laboratory, and Panavance Therapeutics. She is also a board
member of the Foundation for mRNA Medicines.

 

Cynthia Collins holds a Bachelor of Science degree in Microbiology from the
University of Illinois, Urbana and an MBA from The University of Chicago Booth
School of Business.

 

"I am honored to join MaxCyte's Board of Directors, where I believe there is
exceptional work being done to propel the cell and genetic medicine industry
forward," said Cynthia Collins. "I am excited to support the Company's growth
and innovation as they continue to help developers bring a new class of
therapies to market."

 

Regulatory Disclosures

 

In accordance with Rule 17, Schedule Two paragraph (g) of the AIM Rules for
Companies, Cynthia Lynne Collins (66) holds, or has held, the following
directorship or partnerships in the last five years:

 

 Current                                    Past 5 years
 Alanis Therapeutics, Inc.                  Triumvira Immunologics, Inc.
 Nutracker Therapeutics, Inc.               Biocare Medical LLC
 Panavance Therapeutics, Inc.               Human Longevity, Inc.
 The Charles Stark Draper Laboratory, Inc.  Editas Medicine, Inc.
 Poseida Therapeutics, Inc.                 ARM Foundation for Cell and Gene Medicine
 Certara, Inc.
 DermTech Inc.
 The Foundation for MRNA Medicines, Inc.

 

Cynthia Collins, was previously appointed as an independent director to the
Board of DermTech, Inc. on May 24, 2018. On June 18, 2024, the Company filed
for Chapter 11 bankruptcy. On August 21, 2024 the US Bankruptcy Court for the
District of Delaware approved the sale of a substantial amount of DermTech
Inc.'s assets through a court-supervised auction.

 

Save as disclosed above, there is no further information to be disclosed
pursuant to Rule 17 Schedule Two paragraph (g) of the AIM Rules for Companies
in respect of the appointment of Cynthia Collins.

 

 

About MaxCyte

 

At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patients' lives. We have spent more than 20 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today's processes to innovate
tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or disposables;
and software protocols, all supported by a robust worldwide intellectual
property portfolio. By providing our partners with the right technology
platform, as well as scientific, technical and regulatory support, we aim to
guide them on their journey to transform human health. Learn more at
maxcyte.com
(https://protect.checkpoint.com/v2/___https:/maxcyte.com/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzozM2I1YTVmN2I2YTExNzdhYjJiYWQzMzY2ZWJlM2NkNzo2OmE1MjQ6ZjkwYTM4NTFkYzFjZTE4MDc3MzEzMDUxMzdhY2YwMjI4NmExYzRmM2IyYTQ4MGRkNjJhMTZiYmUyNzZkMWE4NDpwOlQ6Rg)
and follow us on X
(https://protect.checkpoint.com/v2/___https:/twitter.com/MaxCyte_info___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzozM2I1YTVmN2I2YTExNzdhYjJiYWQzMzY2ZWJlM2NkNzo2OmNlODY6NGQ3NmQ0ODY5ZWMwZGM2ZWY3YWE0YzdmMzljY2UyODM4ZTExMGI5OWRjODhlYjk5NmI3ZjcyZTNlNTIxZGE4ZDpwOlQ6Rg)
and LinkedIn
(https://protect.checkpoint.com/v2/___https:/www.linkedin.com/company/maxcyte-inc-/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzozM2I1YTVmN2I2YTExNzdhYjJiYWQzMzY2ZWJlM2NkNzo2OmE5Yjg6ODI4ODYyMDRkZDU5YTY0MjUyMzY1NGQwMjczZDA2NTM5YTI1MDcxM2Y4NjgyNWUxODM5YTcxMTc4ZDJkYmRiMDpwOlQ6Rg)
.

 

 

MaxCyte Contacts:

 

US IR Adviser

Gilmartin Group

David Deuchler, CFA

+1 415-937-5400

ir@maxcyte.com (mailto:ir@maxcyte.com)

 

US Media Relations

Spectrum Science

Jordan Vines

jvines@spectrumscience.com (mailto:jvines@spectrumscience.com)

+1 540-629-3137

 

Nominated Adviser and Joint Corporate Broker

Panmure Liberum

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500

 

UK IR Adviser

ICR Consilium

Mary-Jane Elliott

Chris Welsh

+44 (0)203 709 5700

maxcyte@consilium-comms.com (mailto:maxcyte@consilium-comms.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFIFSTITLELIS